Considering its cost-effectiveness and relatively lower performance in HCC prediction, few studies have reported the effectiveness of AFP-L3 combined with AFP and PIVKA-II in the diagnosis of overall and early HCC [8, 37]. The gene discussed is AFP; the disease is hepatocellular carcinoma.